The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Interleukin (IL-6) Immunotherapy
Open accessAbstract
Interleukin 6 (IL-6) is a prototypical cytokine for maintaining homeostasis. When homeostasis is disrupted by infections or tissue injuries, IL-6 is produced immediately and contributes to host defense against such emergent stress through activation of acute-phase and immune responses. However, dysregulated excessive and persistent synthesis of IL-6 has a pathological effect on, respectively, acute systemic inflammatory response syndrome and chronic immune-mediated diseases. The IL-6 inhibitor, tocilizumab, a humanized anti-IL-6 receptor antibody, is currently being used for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, and Castleman disease. Lines of recent evidence strongly suggest IL-6 blockade can provide broader therapeutic strategy for various diseases included in acute systemic and chronic inflammatory diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
IL‐6 in inflammation, immunity, and disease
Tanaka, T., Narazaki, M., & Kishimoto, T. (2014) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a016295 · Cited by 5,046
Self-citationChimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., Vaysbrot, E., McNaughton, C., Osani, M., Shmerling, R. H., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39480 · Cited by 2,777
Interleukin-6 and the acute phase response
Heinrich, P. C., Castell, J. V., & Andus, T. (1990) · Biochemical Journal · doi:10.1042/bj2650621 · Cited by 2,734
Nemeth, E., Rivera, S., Gabayan, V., Keller, C., Taudorf, S., Pedersen, B. K., & Ganz, T. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420945 · Cited by 2,650 · cited 1×
“Moreover, IL-6-induced hepcidin production blocks the action of iron transporter ferroportin 1 on gut and thus reduces serum iron levels (Nemeth et al. 2004), resulting in hypoferremia and anemia associated with chronic inflammation.”
BackgroundCytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
Suntharalingam, G., Perry, M. R., Ward, S., Brett, S. J., Castello-Cortes, A., Brunner, M. D., & Panoskaltsis, N. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa063842 · Cited by 2,164 · cited 1×
“Surgery-related complications, adrenal insufficiency, pulmonary embolism, and aortic aneurysm can also lead to SIRS, and a biological drug against CD28 was also reported to induce SIRS (Suntharalingam et al. 2006).”
BackgroundHirano, T., Yasukawa, K., Harada, H., Taga, T., Watanabe, Y., Matsuda, T., Kashiwamura, S.-I., Nakajima, K., Koyama, K., Iwamatsu, A., et al. (1986) · Nature · doi:10.1038/324073a0 · Cited by 2,139 · cited 1×
“The human IL-6 gene was first cloned as B-cell stimulatory factor 2 (BSF-2), which induces B cells to produce immunoglobulin (Ig) (Kishimoto 1985; Hirano et al. 1986).”
BackgroundSelf-citationKishimoto, T. (1989) · Blood · doi:10.1182/blood.v74.1.1.1 · Cited by 2,069
Self-citationSmolen, J. S., Landewé, R., Bijlsma, J., Burmester, G., Chatzidionysiou, K., Dougados, M., Nam, J., Ramiro, S., Voshaar, M., van Vollenhoven, R., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-210715 · Cited by 2,057
AU-rich elements: characterization and importance in mRNA degradation
Chen, C.-Y. A., & Shyu, A.-B. (1995) · Trends in Biochemical Sciences · doi:10.1016/s0968-0004(00)89102-1 · Cited by 1,948
Smolen, J. S., Landewé, R., Breedveld, F. C., Buch, M., Burmester, G., Dougados, M., Emery, P., Gaujoux-Viala, C., Gossec, L., Nam, J., et al. (2014) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2013-204573 · Cited by 1,763
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633
Self-citationNegative Inotropic Effects of Cytokines on the Heart Mediated by Nitric Oxide
Finkel, M. S., Oddis, C. V., Jacob, T. D., Watkins, S. C., Hattler, B. G., & Simmons, R. L. (1992) · Science · doi:10.1126/science.1631560 · Cited by 1,628
IL‐6: Regulator of Treg/Th17 balance
Kimura, A., & Kishimoto, T. (2010) · European Journal of Immunology · doi:10.1002/eji.201040391 · Cited by 1,595
Self-citationgp 130 AND THE INTERLEUKIN-6 FAMILY OF CYTOKINES
Taga, T., & Kishimoto, T. (1997) · Annual Review of Immunology · doi:10.1146/annurev.immunol.15.1.797 · Cited by 1,461
Self-citationInterleukin-6 in Biology and Medicine
Akira, S., Taga, T., & Kishimoto, T. (1993) · Advances in Immunology · doi:10.1016/s0065-2776(08)60532-5 · Cited by 1,389
Self-citationKishimoto, T., Taga, T., & Akira, S. (1994) · Cell · doi:10.1016/0092-8674(94)90333-6 · Cited by 1,328
Self-citationRole of IL-6 and Its Soluble Receptor in Induction of Chemokines and Leukocyte Recruitment
Romano, M., Sironi, M., Toniatti, C., Polentarutti, N., Fruscella, P., Ghezzi, P., Faggioni, R., Luini, W., van Hinsbergh, V., Sozzani, S., et al. (1997) · Immunity · doi:10.1016/s1074-7613(00)80334-9 · Cited by 1,112
Cloning and Expression of the Human Interleukin-6 (BSF-2/IFNβ 2) Receptor
Yamasaki, K., Taga, T., Hirata, Y., Yawata, H., Kawanishi, Y., Seed, B., Taniguchi, T., Hirano, T., & Kishimoto, T. (1988) · Science · doi:10.1126/science.3136546 · Cited by 1,060
Self-citationStructure and function of a new STAT-induced STAT inhibitor
Naka, T., Narazaki, M., Hirata, M., Matsumoto, T., Minamoto, S., Aono, A., Nishimoto, N., Kajita, T., Taga, T., Yoshizaki, K., et al. (1997) · Nature · doi:10.1038/43219 · Cited by 1,040
Self-citationMolecular cloning and expression of an IL-6 signal transducer, gp130
Hibi, M., Murakami, M., Saito, M., Hirano, T., Taga, T., & Kishimoto, T. (1990) · Cell · doi:10.1016/0092-8674(90)90411-7 · Cited by 1,039
Self-citationInterleukin 6 Induces the Expression of Vascular Endothelial Growth Factor
Cohen, T., Nahari, D., Cerem, L. W., Neufeld, G., & Levi, B.-Z. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.2.736 · Cited by 1,039
INTERLEUKIN-6: From Basic Science to Medicine—40 Years in Immunology
Kishimoto, T. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115806 · Cited by 1,024
Self-citationPathogenic significance of interleukin-6 (IL-6/BSF-2) in Castleman’s disease
Yoshizaki, K., Matsuda, T., Nishimoto, N., Kuritani, T., Taeho, L., Aozasa, K., Nakahata, T., Kawai, H., Tagoh, H., & Komori, T. (1989) · Blood · doi:10.1182/blood.v74.4.1360.1360 · Cited by 928 · cited 2×
“1988), germinal center B cells in swollen lymph nodes of Castleman disease (Yoshizaki et al. 1989), and peripheral blood cells or tissues involved in various other autoimmune and chronic inflammatory diseases and even malignant cells in cancers (Akira et al.”
BackgroundYokota, S., Imagawa, T., Mori, M., Miyamae, T., Aihara, Y., Takei, S., Iwata, N., Umebayashi, H., Murata, T., Miyoshi, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60454-7 · Cited by 789
Self-citationNishimoto, N., Yoshizaki, K., Miyasaka, N., Yamamoto, K., Kawai, S., Takeuchi, T., Hashimoto, J., Azuma, J., & Kishimoto, T. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20303 · Cited by 788
Self-citationExcessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis
Hirano, T., Matsuda, T., Turner, M., Miyasaka, N., Buchan, G., Tang, B., Sato, K., Shimi, M., Maid, R., Feldmann, M., et al. (1988) · European Journal of Immunology · doi:10.1002/eji.1830181122 · Cited by 784
Self-citationRandomized trial of tocilizumab in systemic juvenile idiopathic arthritis
De Benedetti, F., Brunner, H. I., Ruperto, N., Kenwright, A., Wright, S., Calvo, I., Cuttica, R., Ravelli, A., Schneider, R., Woo, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112802 · Cited by 763
Humanized anti–interleukin-6 receptor antibody treatment of multicentric Castleman disease
Nishimoto, N., Kanakura, Y., Aozasa, K., Johkoh, T., Nakamura, M., Nakano, S., Nakano, N., Ikeda, Y., Sasaki, T., Nishioka, K., et al. (2005) · Blood · doi:10.1182/blood-2004-12-4602 · Cited by 754
Self-citationManaging Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Maude, S. L., Barrett, D., Teachey, D. T., & Grupp, S. A. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000035 · Cited by 752
Mauer, J., Chaurasia, B., Goldau, J., Vogt, M. C., Ruud, J., Nguyen, K. D., Theurich, S., Hausen, A. C., Schmitz, J., Brönneke, H. S., et al. (2014) · Nature Immunology · doi:10.1038/ni.2865 · Cited by 727
IL-6-Induced Homodimerization of gp130 and Associated Activation of a Tyrosine Kinase
Murakami, M., Hibi, M., Nakagawa, N., Nakagawa, T., Yasukawa, K., Yamanishi, K., Taga, T., & Kishimoto, T. (1993) · Science · doi:10.1126/science.8511589 · Cited by 724
Self-citationVascular endothelial growth factor induces VE-cadherin tyrosine phosphorylation in endothelial cells
Esser, S., Lampugnani, M. G., Corada, M., Dejana, E., & Risau, W. (1998) · Journal of Cell Science · doi:10.1242/jcs.111.13.1853 · Cited by 715
Immunotherapeutic Implications of Il-6 Blockade for Cytokine Storm
Tanaka, T., Narazaki, M., & Kishimoto, T. (2016) · Immunotherapy · doi:10.2217/imt-2016-0020 · Cited by 708
Self-citationKhanna, D., Denton, C. P., Jahreis, A., van Laar, J. M., Frech, T. M., Anderson, M. E., Baron, M., Chung, L., Fierlbeck, G., Lakshminarayanan, S., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00232-4 · Cited by 683
Gabay, C., Emery, P., van Vollenhoven, R., Dikranian, A., Alten, R., Pavelka, K., Klearman, M., Musselman, D., Agarwal, S., Green, J., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60250-0 · Cited by 672
Interleukin-6 and its receptor: a paradigm for cytokines
Kishimoto, T., Akira, S., & Taga, T. (1992) · Science · doi:10.1126/science.1411569 · Cited by 665
Self-citationZc3h12a is an RNase essential for controlling immune responses by regulating mRNA decay
Matsushita, K., Takeuchi, O., Standley, D. M., Kumagai, Y., Kawagoe, T., Miyake, T., Satoh, T., Kato, H., Tsujimura, T., Nakamura, H., et al. (2009) · Nature · doi:10.1038/nature07924 · Cited by 649
Hexameric Structure and Assembly of the Interleukin-6/IL-6 α-Receptor/gp130 Complex
Boulanger, M. J., Chow, D.-C., Brevnova, E. E., & Garcia, K. C. (2003) · Science · doi:10.1126/science.1083901 · Cited by 642
Teachey, D. T., Rheingold, S. R., Maude, S. L., Zugmaier, G., Barrett, D. M., Seif, A. E., Nichols, K. E., Suppa, E. K., Kalos, M., Berg, R. A., et al. (2013) · Blood · doi:10.1182/blood-2013-02-485623 · Cited by 613
Gillmore, J. D., Lovat, L. B., Persey, M. R., Pepys, M. B., & Hawkins, P. N. (2001) · The Lancet · doi:10.1016/s0140-6736(00)05252-1 · Cited by 595
Villiger, P. M., Adler, S., Kuchen, S., Wermelinger, F., Dan, D., Fiege, V., Bütikofer, L., Seitz, M., & Reichenbach, S. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00560-2 · Cited by 577
The origins, function, and regulation of T follicular helper cells
Ma, C. S., Deenick, E. K., Batten, M., & Tangye, S. G. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120994 · Cited by 552
Kotake, S., Sato, K., Kim, K. J., Takahashi, N., Udagawa, N., Nakamura, I., Yamaguchi, A., Kishimoto, T., Suda, T., & Kashiwazaki, S. (1996) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650110113 · Cited by 545
Self-citationChoy, E. H. S., Isenberg, D. A., Garrood, T., Farrow, S., Ioannou, Y., Bird, H., Cheung, N., Williams, B., Hazleman, B., Price, R., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10623 · Cited by 526 · cited 1×
“The first randomized controlled trial of tocilizumab for RA was performed with 45 patients who received a single intravenous dose of either 0.1, 1, 5, or 10 mg/kg of tocilizumab or placebo (Choy et al. 2002).”
MethodInfluentialSelf-citationChihara, N., Aranami, T., Sato, W., Miyazaki, Y., Miyake, S., Okamoto, T., Ogawa, M., Toda, T., & Yamamura, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017385108 · Cited by 474
Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy
Nishimoto, N., Sasai, M., Shima, Y., Nakagawa, M., Matsumoto, T., Shirai, T., Kishimoto, T., & Yoshizaki, K. (2000) · Blood · doi:10.1182/blood.v95.1.56 · Cited by 441
Self-citationInterleukin-6 is a potent thrombopoietic factor in vivo in mice
Ishibashi, T., Kimura, H., Shikama, Y., Uchida, T., Kariyone, S., Hirano, T., Kishimoto, T., Takatsuki, F., & Akiyama, Y. (1989) · Blood · doi:10.1182/blood.v74.4.1241.1241 · Cited by 432
Self-citationIL-6 and NF-IL6 in acute-phase response and viral infection
Akira, S., & Kishimoto†, T. (1992) · Immunological Reviews · doi:10.1111/j.1600-065x.1992.tb01407.x · Cited by 411
Self-citationActivation of Interleukin-6 Gene Expression through the NF-κB Transcription Factor
Libermann, T. A., & Baltimore, D. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.5.2327-2334.1990 · Cited by 403
Kleveland, O., Kunszt, G., Bratlie, M., Ueland, T., Broch, K., Holte, E., Michelsen, A. E., Bendz, B., Amundsen, B. H., Espevik, T., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw171 · Cited by 400
Mino, T., Murakawa, Y., Fukao, A., Vandenbon, A., Wessels, H.-H., Ori, D., Uehata, T., Tartey, S., Akira, S., Suzuki, Y., et al. (2015) · Cell · doi:10.1016/j.cell.2015.04.029 · Cited by 390
Schmitz, J., Weissenbach, M., Haan, S., Heinrich, P. C., & Schaper, F. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.17.12848 · Cited by 388 · cited 1×
“STAT3 also induces the suppressor of cytokine signaling (SOCS)1 and SOCS3, which bind to tyrosine-phosphorylated JAK (Naka et al. 1997) and tyrosine-phosphorylated gp130 (Schmitz et al. 2000), respectively, to stop IL-6 signaling by means of a negative feedback loop.”
BackgroundPost-transcriptional control of cytokine production
Anderson, P. (2008) · Nature Immunology · doi:10.1038/ni1584 · Cited by 376
The Biology and Medical Implications of Interleukin-6
Tanaka, T., & Kishimoto, T. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0022 · Cited by 375
Self-citationRole of interleukin 6 in myocardial dysfunction of meningococcal septic shock
Pathan, N., Hemingway, C. A., Alizadeh, A. A., Stephens, A. C., Boldrick, J. C., Oragui, E. E., McCabe, C., Welch, S. B., Whitney, A., O'Gara, P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(03)15326-3 · Cited by 362
Factors Affecting B-Cell Growth and Differentiation
Kishimoto, T. (1985) · Annual Review of Immunology · doi:10.1146/annurev.iy.03.040185.001025 · Cited by 359
Self-citationIgawa, T., Ishii, S., Tachibana, T., Maeda, A., Higuchi, Y., Shimaoka, S., Moriyama, C., Watanabe, T., Takubo, R., Doi, Y., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1691 · Cited by 353
Hirano, T., Taga, T., Yasukawa, K., Nakajima, K., Nakano, N., Takatsuki, F., Shimizu, M., Murashima, A., Tsunasawa, S., & Sakiyama, F. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.1.228 · Cited by 351
Hashizume, M., Hayakawa, N., & Mihara, M. (2008) · Rheumatology · doi:10.1093/rheumatology/ken363 · Cited by 347
Narazaki, M., Yasukawa, K., Saito, T., Ohsugi, Y., Fukui, H., Koishihara, Y., Yancopoulos, G., Taga, T., & Kishimoto, T. (1993) · Blood · doi:10.1182/blood.v82.4.1120.1120 · Cited by 343
Self-citationProtective Effects of IL-6 Blockade in Sepsis Are Linked to Reduced C5a Receptor Expression
Riedemann, N. C., Neff, T. A., Guo, R.-F., Bernacki, K. D., Laudes, I. J., Sarma, J. V., Lambris, J. D., & Ward, P. A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.1.503 · Cited by 330
Effect of Human Recombinant Interleukin-6 and Interleukin-8 on Monocyte Procoagulant Activity
Neumann, F.-J., Ott, I., Marx, N., Luther, T., Kenngott, S., Gawaz, M., Kotzsch, M., & Schömig, A. (1997) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.17.12.3399 · Cited by 308
Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study
Araki, M., Matsuoka, T., Miyamoto, K., Kusunoki, S., Okamoto, T., Murata, M., Miyake, S., Aranami, T., & Yamamura, T. (2014) · Neurology · doi:10.1212/wnl.0000000000000317 · Cited by 284
Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth.
Sato, K., Tsuchiya, M., Saldanha, J. W., Koishihara, Y., Ohsugi, Y., Kishimoto, T., & Bendig, M. M. (1993) · PubMed · Cited by 274
Self-citationTherapeutic Targeting of the Interleukin-6 Receptor
Tanaka, T., Narazaki, M., & Kishimoto, T. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010611-134715 · Cited by 262
Self-citationHashimoto-Kataoka, T., Hosen, N., Sonobe, T., Arita, Y., Yasui, T., Masaki, T., Minami, M., Inagaki, T., Miyagawa, S., Sawa, Y., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424774112 · Cited by 260
Self-citationScala, G., Ruocco, M. R., Ambrosino, C., Mallardo, M., Giordano, V, Baldassarre, F., Dragonetti, E., Quinto, I., & Venuta, S. (1994) · The Journal of experimental medicine · doi:10.1084/jem.179.3.961 · Cited by 242
Interleukin-6 Causes Endothelial Barrier Dysfunction via the Protein Kinase C Pathway
Desai, T. R., Leeper, N. J., Hynes, K. L., & Gewertz, B. L. (2002) · Journal of Surgical Research · doi:10.1006/jsre.2002.6415 · Cited by 235
Arid5a controls IL-6 mRNA stability, which contributes to elevation of IL-6 level in vivo
Masuda, K., Ripley, B., Nishimura, R., Mino, T., Takeuchi, O., Shioi, G., Kiyonari, H., & Kishimoto, T. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1307419110 · Cited by 226
Self-citationHe, M., Xu, Z., Ding, T., Kuang, D.-M., & Zheng, L. (2009) · Cellular & Molecular Immunology · doi:10.1038/cmi.2009.45 · Cited by 198
Shima, Y., Kuwahara, Y., Murota, H., Kitaba, S., Kawai, M., Hirano, T., Arimitsu, J., Narazaki, M., Hagihara, K., Ogata, A., et al. (2010) · Rheumatology · doi:10.1093/rheumatology/keq275 · Cited by 195
Self-citationExpression and Function of C5a Receptor in Mouse Microvascular Endothelial Cells
Laudes, I. J., Chu, J. C., Huber-Lang, M., Guo, R.-F., Riedemann, N. C., Sarma, J. V., Mahdi, F., Murphy, H. S., Speyer, C., Lu, K. T., et al. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.10.5962 · Cited by 181
Ballard, D., Bohnlein, E., Lowenthal, J., Wano, Y., Franza, B., & Greene, W. (1988) · Science · doi:10.1126/science.241.4873.1652 · Cited by 176
Devauchelle-Pensec, V., Berthelot, J. M., Cornec, D., Renaudineau, Y., Marhadour, T., Jousse-Joulin, S., Querellou, S., Garrigues, F., De Bandt, M., Gouillou, M., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2015-208742 · Cited by 171
A new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategy
Tanaka, T., Narazaki, M., Ogata, A., & Kishimoto, T. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.009 · Cited by 164
Self-citationZhang, C., Xin, H., Zhang, W., Yazaki, P. J., Zhang, Z., Le, K., Li, W., Lee, H., Kwak, L. W., Forman, S. J., et al. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.003 · Cited by 148
Lally, L., Forbess, L. J., Hatzis, C., & Spiera, R. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39740 · Cited by 124
Interleukin-6 in Sepsis and Capillary Leakage Syndrome
Krüttgen, A., & Rose‐John, S. (2011) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2011.0062 · Cited by 111
FDA Approval: Siltuximab for the Treatment of Patients with Multicentric Castleman Disease
Deisseroth, A., Ko, C., Nie, L., Zirkelbach, J. F., Zhao, L. Y., Bullock, J. M., Mehrotra, N., Valle, P. D., Saber, H., Sheth, C. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1678 · Cited by 105
Arid5a regulates naive CD4+ T cell fate through selective stabilization of Stat3 mRNA
Masuda, K., Ripley, B., Nyati, K. K., Dubey, P. K., Zaman, M. M.-U., Hanieh, H., Higa, M., Yamashita, K., Standley, D. M., Mashima, T., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20151289 · Cited by 88
Self-citationTanaka, T., Ogata, A., & Narazaki, M. (2013) · Clinical Medicine Insights Therapeutics · doi:10.4137/cmt.s9282 · Cited by 23
Self-citation
Cited by
Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms
Kang, S., & Kishimoto, T. (2021) · Experimental & Molecular Medicine · doi:10.1038/s12276-021-00649-0 · Cited by 375
Self-citationCritical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis
Ramasamy, S., & Subbian, S. (2021) · Clinical Microbiology Reviews · doi:10.1128/cmr.00299-20 · Cited by 289
Interleukin-6: obstacles to targeting a complex cytokine in critical illness
McElvaney, O. J., Curley, G. F., Rose-John, S., & McElvaney, N. G. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00103-x · Cited by 278
Roberts, M. B., & Fishman, J. A. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1189 · Cited by 277
Dynamic lipidome alterations associated with human health, disease and ageing
Hornburg, D., Wu, S., Moqri, M., Zhou, X., Contrepois, K., Bararpour, N., Traber, G. M., Su, B., Metwally, A. A., Avina, M., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00880-1 · Cited by 260
Metadata
- Authors
- Tanaka, T., Narazaki, M., & Kishimoto, T.
- Venue
- Cold Spring Harbor Perspectives in Biology
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2017-08-04
- Volume
- 10
- Issue
- 8
- Pages
- a028456
- ISSN
- 1943-0264 (ISSN-L)
- OpenAlex
- W2744892122
- Cited by
- 407
- References
- 83
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.